Sarah Betrian

IUCT Oncopole
Toulouse, FR 
IUCT Oncopole
Toulouse, FR 
OverviewLocationsClinical Research

Overview

Sarah Betrian practices in Toulouse, France. Her top areas of expertise are Desmoplastic Small Round Cell Tumor, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, and Lymphadenectomy.

Her clinical research consists of co-authoring 33 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

IUCT Oncopole
Toulouse, 31059, France
Other Locations
CHU Limoges
Limoges, 87000, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy
Efficacy of Regorafenib as Maintenance Therapy in Non-adipocytic Soft Tissue Sarcoma Having Received First-line Doxorubicin-based Chemotherapy
Enrollment Status: Completed
Publish Date: December 10, 2024
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
A European, Multi-centre Phase II Trial of Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck (HNSCC)
A European, Multi-centre Phase II Trial of Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck (HNSCC)
Enrollment Status: Unknown
Publish Date: September 28, 2023
Intervention Type: Drug
Study Drugs: Atezolizumab, Bevacizumab
Study Phase: Phase 2
NP137 - An Open-label, First in Human, Phase I Trial Aiming to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of a Humanized Monoclonal Antibody Targeting Netrin 1 (NP137) in Patients With Advanced/Metastatic Solid Tumors.
NP137 - An Open-label, First in Human, Phase I Trial Aiming to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of a Humanized Monoclonal Antibody Targeting Netrin 1 (NP137) in Patients With Advanced/Metastatic Solid Tumors.
Enrollment Status: Completed
Publish Date: July 25, 2022
Intervention Type: Drug
Study Drug: NP137
Study Phase: Phase 1
View 2 Less Clinical Trials

33 Total Publications

Presentation of the ENDO-SFOG CAMPUS app: An easy therapeutic decision support app in endometrial cancer created by the French Society of Young Gynecological Oncologists (SFOG Campus).
Presentation of the ENDO-SFOG CAMPUS app: An easy therapeutic decision support app in endometrial cancer created by the French Society of Young Gynecological Oncologists (SFOG Campus).
Journal: Journal of gynecology obstetrics and human reproduction
Published: January 11, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Betrian's expertise for a condition
ConditionClose
        View All 7 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile